Use of FEF25–75% to Guide IgG Dosing to Protect Pulmonary Function in CVID

Academic Article


  • © 2020, Springer Science+Business Media, LLC, part of Springer Nature. Immunoglobulin replacement therapy (IGRT) can protect against lung function decline in CVID. We tested whether increasing IgG dosage was beneficial in patients who exhibited a decline in forced expiratory flow at 25–75% (FEF25–75%) even though they were receiving IgG doses within the therapeutic range. Of 189 CVID patients seen over 12 years, 38 patients met inclusion criteria, were seen on ≥ 3 visits, and demonstrated a ≥ 10% decrease in FEF25–75% from visits 1 to 2. FEF25–75%, forced expiratory flow at 1 s (FEV1), and FEV1/FVC at visit 3 were compared among those with non-dose adjustment (non-DA) versus additional IgG dose adjustment (DA). Three FEF25–75% tiers were identified: top (> 80% predicted), middle (50–80%), and bottom (< 50%). DA and non-DA groups did not differ in clinical infections or bronchodilator use, although the non-DA group tended to use more antibiotics. In the top, normal tier, FEF25–75% increased in DA, but the change did not achieve statistical significance. In the middle moderate obstruction tier, visit 3 FEF25–75% increased among DA but not non-DA sets (11.8 ± 12.4%, p = 0.003 vs. 0.3 ± 9.9%, p = 0.94). Improvement in FEV1/FVC at visit 3 was also significant among DA vs. non-DA (7.2 ± 12.4%, p = 0.04 vs. − 0.2 ± 2.7%, p = 0.85). In the bottom, severe tier, FEF25–75% was unchanged in DA (− 0.5 ± 5.2%, p = 0.79), but increased in non-DA (5.1 ± 5.2%, p = 0.02). Among IGRT CVID patients with moderate but not severe obstruction as assessed by spirometry, increasing IgG dosage led to an increase in FEF25–75% and FEV1/FVC.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Hwangpo T; Wang Z; Ghably J; Bhatt SP; Cui X; Schroeder HW